JW Shinyak Corporation (067290) - Total Liabilities
Based on the latest financial reports, JW Shinyak Corporation (067290) has total liabilities worth ₩26.02 Billion KRW (≈ $17.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JW Shinyak Corporation - Total Liabilities Trend (2007–2024)
This chart illustrates how JW Shinyak Corporation's total liabilities have evolved over time, based on quarterly financial data. See JW Shinyak Corporation working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
JW Shinyak Corporation Competitors by Total Liabilities
The table below lists competitors of JW Shinyak Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Drilling Tools International Corp.
NASDAQ:DTI
|
USA | $104.27 Million |
|
Applied BioCode
TW:6598
|
Taiwan | NT$343.23 Million |
|
Masisa
SN:MASISA
|
Chile | CL$199.35 Million |
|
Globrands Group Ltd
TA:GLRS
|
Israel | ILA570.15 Million |
|
Daesung Holdin
KO:016710
|
Korea | ₩474.66 Billion |
|
Asahimas Flat Glass Tbk
JK:AMFG
|
Indonesia | Rp2.68 Trillion |
|
ZK International Group Co Ltd
NASDAQ:ZKIN
|
USA | $38.25 Million |
|
Gain Therapeutics Inc
NASDAQ:GANX
|
USA | $4.73 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down JW Shinyak Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see JW Shinyak Corporation (067290) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JW Shinyak Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JW Shinyak Corporation (2007–2024)
The table below shows the annual total liabilities of JW Shinyak Corporation from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩36.14 Billion ≈ $24.49 Million |
-26.52% |
| 2023-12-31 | ₩49.17 Billion ≈ $33.32 Million |
+29.00% |
| 2022-12-31 | ₩38.12 Billion ≈ $25.83 Million |
+4.27% |
| 2021-12-31 | ₩36.56 Billion ≈ $24.78 Million |
-8.07% |
| 2020-12-31 | ₩39.77 Billion ≈ $26.95 Million |
-43.76% |
| 2019-12-31 | ₩70.71 Billion ≈ $47.92 Million |
-6.61% |
| 2018-12-31 | ₩75.72 Billion ≈ $51.31 Million |
-12.49% |
| 2017-12-31 | ₩86.53 Billion ≈ $58.64 Million |
-17.60% |
| 2016-12-31 | ₩105.01 Billion ≈ $71.16 Million |
+20.08% |
| 2015-12-31 | ₩87.45 Billion ≈ $59.26 Million |
+3.45% |
| 2014-12-31 | ₩84.53 Billion ≈ $57.29 Million |
+3.88% |
| 2013-12-31 | ₩81.38 Billion ≈ $55.15 Million |
+23.04% |
| 2012-12-31 | ₩66.14 Billion ≈ $44.82 Million |
+32.31% |
| 2011-12-31 | ₩49.99 Billion ≈ $33.88 Million |
+135.31% |
| 2008-12-31 | ₩21.24 Billion ≈ $14.40 Million |
-0.58% |
| 2007-12-31 | ₩21.37 Billion ≈ $14.48 Million |
-- |
About JW Shinyak Corporation
JW Shinyak Corporation, a pharmaceutical company, engages in the production and sale of medicines and medical supplies in South Korea. The company offers pharmaceutical products in the areas of dermatology, urology, pediatrics, otolaryngology, etc.; and cardiovascular, gastrointestinal, urinary, NSAIDs, antibiotics, anti-fungal, anti-viral, respiratory, antihistamines, steroid hormone, anti-obesi… Read more